The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung-Yong Kim | - |
dc.contributor.author | Sung Hwa Bae | - |
dc.contributor.author | Soo-Mee Bang | - |
dc.contributor.author | Ki-Seong Eom | - |
dc.contributor.author | Junshik Hong | - |
dc.contributor.author | Seongsoo Jang | - |
dc.contributor.author | Chul Won Jung | - |
dc.contributor.author | Hee-Jin Kim | - |
dc.contributor.author | Ho Young Kim | - |
dc.contributor.author | Min Kyoung Kim | - |
dc.contributor.author | Soo-Jeong Kim | - |
dc.contributor.author | Yeung-Chul Mun | - |
dc.contributor.author | Seung-Hyun Nam | - |
dc.contributor.author | Jinny Park | - |
dc.contributor.author | Jong-Ho Won | - |
dc.contributor.author | Chul Won Choi | - |
dc.date.available | 2021-01-27T01:40:29Z | - |
dc.date.created | 2020-12-30 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79828 | - |
dc.description.abstract | In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한내과학회 | - |
dc.relation.isPartOf | The Korean Journal of Internal Medicine | - |
dc.title | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | - |
dc.title.alternative | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000605630300006 | - |
dc.identifier.doi | 10.3904/kjim.2020.319 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.36, no.1, pp.45 - 62 | - |
dc.identifier.kciid | ART002660572 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85099166939 | - |
dc.citation.endPage | 62 | - |
dc.citation.startPage | 45 | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 36 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Jinny Park | - |
dc.subject.keywordAuthor | Polycythemia vera | - |
dc.subject.keywordAuthor | Thrombocythemia | - |
dc.subject.keywordAuthor | essential | - |
dc.subject.keywordAuthor | Primary myelofibrosis | - |
dc.subject.keywordAuthor | Practice guideline | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.